Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 5/20 | 0.58 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.58 |
| ▸ | TACR3 | P29371 | 7/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TACR2 | P21452 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3585355 | 0.91 | DHODH (0.54) | DHODHPDE10ATACR3TSHRLMNA | |
| SCHEMBL3577055 | 0.87 | TACR3 (0.65) | DHODHPDE10ATACR3TSHRLMNA | |
| SCHEMBL3629848 | 0.85 | DHODH (0.53) | DHODHPDE10ATACR3TSHRLMNA | |
| SCHEMBL3591336 | 0.85 | DHODH (0.53) | DHODHPDE10ATACR3TSHRLMNA | |
| SCHEMBL3594333 | 0.83 | DHODH (0.51) | DHODHPDE10ATACR3TSHRLMNA | |
| SCHEMBL3580239 | 0.82 | DHODH (0.58) | DHODHPDE10ATACR3TSHRLMNA | |
| SCHEMBL3589665 | 0.81 | DHODH (0.57) | DHODHPDE10ATACR3TSHRLMNA | |
| SCHEMBL3580153 | 0.81 | DHODH (0.57) | DHODHPDE10ATACR3TSHRLMNA | |
| SCHEMBL3580968 | 0.81 | PDE10A (0.56) | DHODHPDE10ATACR3TSHRLMNA | |
| SCHEMBL5123788 | 0.77 | DHODH (0.54) | DHODHPDE10ATACR3TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101370782-A | Alkylsulphonamide quinolines | ASTRAZENECA AB (SE) | 2009-02-18 | — | — | CN | claimed |
| US-20080293765-A1 | Alkylsulphonamide Quinolines | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | claimed |
| EP-1968944-A1 | ALKYLSULPHONAMIDE QUINOLINES | AstraZeneca AB (SE) | 2008-09-17 | — | — | EP | claimed |
| US-20080021062-A1 | Alkylsulphonamide Quinolines | ASTRAZENECA AB (SE) | 2008-01-24 | — | — | US | claimed |
| WO-2007069977-A1 | ALKYLSULPHONAMIDE QUINOLINES | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | claimed |
| US-8071621-B2 | Alkylsulphonamide quinolines | ASTRAZENECA AB (SE) | 2011-12-06 | — | — | US | disclosed |
| US-20100029717-A1 | Alkylsulphonamide Quinolines | SIMPSON THOMAS | 2010-02-04 | — | — | US | disclosed |
| US-7608628-B2 | Alkylsulphonamide quinolines | ASTRAZENECA AB (SE) | 2009-10-27 | — | — | US | disclosed |
| CN-101370782-A | Alkylsulphonamide quinolines | ASTRAZENECA AB (SE) | 2009-02-18 | — | — | CN | disclosed |
| US-20080293765-A1 | Alkylsulphonamide Quinolines | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| EP-1968944-A1 | ALKYLSULPHONAMIDE QUINOLINES | AstraZeneca AB (SE) | 2008-09-17 | — | — | EP | disclosed |
| US-20080021062-A1 | Alkylsulphonamide Quinolines | ASTRAZENECA AB (SE) | 2008-01-24 | — | — | US | disclosed |
| WO-2007069977-A1 | ALKYLSULPHONAMIDE QUINOLINES | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021062-A1 | Alkylsulphonamide Quinolines | RECQL, NQO2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | DHODH 2436/4885PDE10A 614/4885TACR3 1038/4885 |
| US-20080293765-A1 | Alkylsulphonamide Quinolines | RECQL, NQO2, QDPR | DHODH 2352/4885PDE10A 609/4885TACR3 673/4885 |
| US-20100029717-A1 | Alkylsulphonamide Quinolines | RECQL, NQO2, QDPR | DHODH 2352/4885PDE10A 609/4885TACR3 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.